Bevacizumab-Based Therapies in the First-Line Treatment of Metastatic Colorectal Cancer

The Oncologist, 04/26/2012

Bevacizumab has demonstrated efficacy in combination with a number of different backbone chemotherapy regimens, and its widespread use has introduced several important questions regarding the selection and optimization of bevacizumab–based treatment regimens, its use in various patient populations, and the identification of associated adverse events.

Author Commentary

This review article addresses several controversies in the first line use of bevacizumab for metastatic colorectal cancer, and discusses recent research efforts to identify biomarkers of treatment sensitivity and resistance.

Print Article Summary Cat 2 CME Report